Sugi Predict

Sugi Predict / Compounds / SCHEMBL14948753

SCHEMBL14948753

SCHEMBL14948753

CCOC(=O)c1sc2c(c1C)c(=O)n(C(C)(C)C(=O)OC(C)(C)C)c(=O)n2CC(O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ ACACA Q13085 6/20 0.48
▸ ACACB O00763 4/20 0.48
▸ ADORA2B P29275 2/20 0.47
▸ PDE4A P27815 2/20 0.39
▸ PDE4B Q07343 2/20 0.39
▸ PDE4C Q08493 2/20 0.39
▸ PDE4D Q08499 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ PDE3B Q13370 1/20 0.39
▸ PDE3A Q14432 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14936497 0.91 MEN1 (0.52) MEN1KMT2AACACAACACBADORA2B
SCHEMBL14936499 0.91 MEN1 (0.52) MEN1KMT2AACACAACACBADORA2B
SCHEMBL14948755 0.91 MEN1 (0.52) MEN1KMT2AACACAACACBADORA2B
SCHEMBL14945766 0.90 ACACB (0.51) MEN1KMT2AACACAACACBADORA2B
SCHEMBL14945788 0.90 ACACB (0.51) MEN1KMT2AACACAACACBADORA2B
SCHEMBL14950686 0.88 ACACA (0.47) MEN1KMT2AACACAACACBADORA2B
SCHEMBL14945792 0.88 ACACA (0.47) MEN1KMT2AACACAACACBADORA2B
SCHEMBL14945484 0.88 ACACA (0.47) MEN1KMT2AACACAACACBADORA2B
SCHEMBL16920293 0.88 ACACB (0.48) ACACAACACBADORA2B
SCHEMBL14945476 0.87 ACACB (0.46) MEN1KMT2AACACAACACBADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10472374-B2 ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2019-11-12 — — US disclosed
EP-3329919-B1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO LLC (US) 2019-11-06 — — EP disclosed
US-20190016732-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. 2019-01-17 — — US disclosed
EP-3329919-A1 ACC INHIBITORS AND USES THEREOF Gilead Apollo, LLC (US) 2018-06-06 — — EP disclosed
US-9944655-B2 ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2018-04-17 — — US disclosed
US-20160297834-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2016-10-13 — — US disclosed
US-20150203510-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2015-07-23 — — US disclosed
US-8969557-B2 ACC inhibitors and uses thereof Nimbus Apollo, Inc. (US) 2015-03-03 — — US disclosed
US-20130123231-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. (US) 2013-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203510-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 MEN1 4200/4885KMT2A 2071/4885ACACA 1/4885
US-10472374-B2 ACC inhibitors and uses thereof ACACA, ACACB, ACAT2 MEN1 4200/4885KMT2A 2071/4885ACACA 1/4885
US-20190016732-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 MEN1 4200/4885KMT2A 2071/4885ACACA 1/4885
US-20130123231-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 MEN1 4200/4885KMT2A 2071/4885ACACA 1/4885
US-20160297834-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 MEN1 4200/4885KMT2A 2071/4885ACACA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.